What does CGC mean in CANCER

The Cancer Genomics Consortium (CGC) is an international network of multidisciplinary investigators focused on the application of genomics to understanding and managing cancer. Our members seek to apply state-of-the-art technologies to probe the genetic and molecular basis of cancer, and are dedicated to helping develop innovative treatments for this disease.

The CGC strives to bring together researchers from diverse fields who are knowledgeable in both genomic science as well as cancer biology. We conduct research projects that involve interdisciplinary collaborations from different institutions. Our primary goal is to promote the development of new research tools, methods, and databases for characterizing the cellular basis of tumorigenesis.

CGC actively participates in major collaborations with external partners such as pharmaceutical companies, hospitals and patient advocacy groups. These partnerships allow access to a wide range of clinical data sets, as well as facilitate cooperation towards difficult projects involving complex datasets or technical challenges.

Advances in genomics have enabled us to develop better strategies for understanding cancer at a molecular level and have impacted treatment strategies. Genomic studies have revealed deep insights into how tumors evolve over time and how they respond differently to various therapies. This has allowed clinicians to select treatments tailored directly towards individual patients based on their genetic profiles.

We provide researchers within our consortium with computational resources aimed at facilitating genomic analysis. We also maintain a comprehensive online resource repository that includes curated information about laboratories within our consortium, public datasets related to tumorigenesis, open source software packages for analyzing genomic data, managed discussion forums related to precision medicine initiatives, and newsletters highlighting recent developments in our field.

The scope of cancers that we focus on includes but is not limited to breast cancer, colorectal cancer, ovarian cancer, melanoma and lung cancer. We strive to develop resources relevant across all types of cancers which can be used by our members when conducting their research.

Yes! Joining the CGC requires applicants to submit a brief description outlining their experience working with genomics as well as any current or prior involvement with other organizations devoted towards precision medicine initiatives. Additionally all applicants must agree upon a confidentiality agreement before being approved as a member.

Yes! We host various workshops both online and at our headquarters where attendees can gain mentorship from experienced professionals regarding modern techniques for studying tumor formation through omics technologies such as transcriptomics and proteomics. Additionally we regularly invite expert speakers from outside institutions that share their knowledge about recent developments in our field.

Yes! We frequently host lectures given by experts in our field on topics ranging from novel approaches for treating certain types of cancers through personalized medicine initiatives to effective strategies for managing large-scale data generated by modern omics technologies such as next-generation sequencing (NGS).